Curcumin: A Case Study in Missed Translation

Curcumin, the active compound in turmeric, sits at the center of a modern paradox. Thousands of patents and an immense body of preclinical research highlight its anti-inflammatory, antioxidant, and anti-cancer potential—yet no curcumin-based drug has emerged from clinical trials.

The reason is structural, not botanical. Curcumin shows poor bioavailability, rapid metabolism, and formulation challenges that clash with the single-molecule drug model. Traditional systems never used turmeric in isolation, pairing it with fats and bioavailability enhancers.

Curcumin may not be a drug failure—but a signal that our development frameworks need rethinking.

#Curcumin #DrugDevelopment #NaturalProducts #ClinicalResearch #IntegrativeMedicine